Clinical Trial Identifier Study Name Study Start Year Investigated Drug Prostate cancer disease No. participants No. EAM No. EAM % EAM No. AAM %AAM
NCT0292318079 MGA271 2017 Enobilituzumab Localized Intermediate and High Risk PCa 32 32 30 93.8% 1 3.1%
NCT0295253480 TRITON 2 2017 Rucaparib mCRPC 277 277 198 71.5% 16 5.8%
NCT0298754381 PROfound 2017 Olaparib mCRPC 387 387 248 64.1% 8 2.1%
NCT0301631282 IMbassadore250 2017 Atezolizumab mCRPC 771 771 577 74.8% 15 2.0%
NCT0309342883 2017 Pembrolizumab mCRPC 42 42 39 92.9% 0 0.0%
NCT0314879584 TALAPRO-1 2017 Talazoparib mCRPC 127 127 110 86.6% 4 3.2%
NCT0317941085 PICK-NEPC 2017 Avelumab 15 15 11 73.3% 4 26.7%
NCT0320481286 2017 Durvalumab and Tremelimumab mCRPC 26 26 22 84.6% 2 7.7%
NCT0333879087 CheckMate 9KD 2018 Nivolumab mCRPC 292 292 248 84.9% 15 5.1%
NCT0340685888 2018 Pembrolizumab and HER2Bi-Armed Activated T Cells mCRPC 13 13 12 92.3% 1 7.7%
NCT0351166489 VISION 2018 177Lu-PSMA-617 mCRPC 831 831 721 86.8% 55 6.6%
NCT0351681290 2018 Olaparib CRPC 36 36 25 69.4% 1 2.8%
NCT0408955391 2019 AZD4635, Oleclumab and Duravalumab mCRPC 59 59 47 79.7% 8 13.6%
Total 2908 2908 2288 78.7% 130 4.5%